Statins and other agents for vascular inflammation

Journal of Vascular Surgery

Volumn 56, Issue 6, 2012, Pages 1799-1806

  Owens, Christopher D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CANAKINUMAB; CHOLESTEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; ROSUVASTATIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE MARKER; HEART INFARCTION; HUMAN; MEDLINE; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; VASCULITIS;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; RISK FACTORS;

EID: 84870240106     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2012.08.045     Document Type: Article

References (56)

1. P. Libby, P.M. Ridker, G.K. Hansson Leducq Transatlantic Network on Atherothrombosis Inflammation in atherosclerosis: from pathophysiology to practice J Am Coll Cardiol 54 2009 2129 2138
2. J.S. Pober, W.C. Sessa Evolving functions of endothelial cells in inflammation Nat Rev Immunol 7 2007 803 815
3. A.D. Pradhan, S. Shrivastava, N.R. Cook, N. Rifai, M.A. Creager, P.M. Ridker Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk Circulation 117 2008 823 831
4. D.Y. Ho, N.R. Cook, K.A. Britton, E. Kim, M.A. Creager, P.M. Ridker High-molecular-weight and total adiponectin levels and incident symptomatic peripheral artery disease in women: a prospective investigation Circulation 124 2011 2303 2311
5. R.G. DePalma, V.W. Hayes, H.T. Cafferata, H.A. Mohammadpour, B.K. Chow, L.R. Zacharski Cytokine signatures in atherosclerotic claudicants J Surg Res 111 2003 215 221
6. M.M. McDermott, J.M. Guralnik, A. Corsi, M. Albay, C. Macchi, S. Bandinelli Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study Am Heart J 150 2005 276 281
7. I. Tzoulaki, G.D. Murray, A.J. Lee, A. Rumley, G.D. Lowe, F.G. Fowkes C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh artery study Circulation 112 2005 976 983
8. Emerging Risk Factors Collaboration S. Kaptoge, E. Di Angelantonio, G. Lowe, M.B. Pepys, S.G. Thompson et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet 375 2010 132 140
9. P.M. Ridker C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus J Am Coll Cardiol 49 2007 2129 2138
10. P.M. Ridker, N. Cook Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores Circulation 109 2004 1955 1959
11. P.W. Wilson, B.H. Nam, M. Pencina, R.B. D'Agostino, E.J. Benjamin, C.J. O'Donnell C-reactive protein and risk of cardiovascular disease in men and women from the Framingham heart study Arch Intern Med 165 2005 2473 2478
12. J. Danesh, J.G. Wheeler, G.M. Hirschfield, S. Eda, G. Eiriksdottir, A. Rumley C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N Engl J Med 350 2004 1387 1397
13. J.P. Casas, T. Shah, J. Cooper, E. Hawe, A.D. McMahon, D. Gaffney Insight into the nature of the CRP-coronary event association using Mendelian randomization Int J Epidemiol 35 2006 922 931
14. T.A. Pearson, G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon, M. Criqui Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and Prevention and the American Heart Association Circulation 107 2003 499 511
15. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
16. Heart Protection Study Collaborative Group Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions J Vasc Surg 45 2007 645 654 discussion:653-4
17. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
18. K. Prasad C-reactive protein (CRP)-lowering agents Cardiovasc Drug Rev 24 2006 33 50
19. P.M. Ridker, C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, C.H. McCabe C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
20. M.K. Jain, P.M. Ridker Anti-inflammatory effects of statins: clinical evidence and basic mechanisms Nat Rev Drug Discov 4 2005 977 987
21. L.X. Cubeddu, M.J. Seamon Statin withdrawal: clinical implications and molecular mechanisms Pharmacotherapy 26 2006 1288 1296
22. P.M. Ridker, N. Rifai, M.A. Pfeffer, F.M. Sacks, L.A. Moye, S. Goldman Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels Cholesterol and recurrent events (CARE) investigators Circulation 98 1998 839 844
23. P.M. Ridker, N. Rifai, M. Clearfield, J.R. Downs, S.E. Weis, J.S. Miles Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965
24. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen, B.G. Brown, P. Ganz, R.A. Vogel Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080
25. S.E. Nissen Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) trial Am J Cardiol 96 2005 61F 68F
26. D.A. Morrow, J.A. de Lemos, M.S. Sabatine, S.D. Wiviott, M.A. Blazing, A. Shui Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial Circulation 114 2006 281 288
27. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto, J.J. Kastelein Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
28. P. Amarenco, O. Benavente, L.B. Goldstein, A. Callahan, H. Sillesen, M.G. Hennerici Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes Stroke 40 2009 1405 1409
29. P. Amarenco, J. Bogousslavsky, A. Callahan, L.B. Goldstein, M. Hennerici, A.E. Rudolph High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
30. J. Kennedy, H. Quan, A.M. Buchan, W.A. Ghali, T.E. Feasby Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients Stroke 36 2005 2072 2076
31. M.L. Melamed, P. Muntner, E.D. Michos, J. Uribarri, C. Weber, J. Sharma Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004 Arterioscler Thromb Vasc Biol 28 2008 1179 1185
32. J. Melzer, R. Brignoli, C. Diehm, J. Reichling, D.D. Do, R. Saller Treating intermittent claudication with Tibetan medicine Padma 28: does it work? Atherosclerosis 189 2006 39 46
33. J.C. Tardif, J.J. McMurray, E. Klug, R. Small, J. Schumi, J. Choi Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial Lancet 371 2008 1761 1768
34. P.W. Serruys, H.M. García-García, P. Buszman, P. Erne, S. Verheye, M. Aschermann Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque Circulation 118 2008 1172 1182
35. P.M. Ridker Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) J Thromb Haemost 7 Suppl 1 2009 332 339
36. P.M. Ridker, T. Thuren, A. Zalewski, P. Libby Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Am Heart J 162 2011 597 605
37. D.C. Crossman, A.C. Morton, J.P. Gunn, J.P. Greenwood, A.S. Hall, K.A. Fox Investigation of the effect of interleukin-1 receptor antagonist (IL-1RA) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART study) Trials 9 2008 8
38. H.K. Choi, M.A. Hernán, J.D. Seeger, J.M. Robins, F. Wolfe Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study Lancet 359 2002 1173 1177
39. B.A. Golomb, T.T. Dang, M.H. Criqui Peripheral arterial disease: morbidity and mortality implications Circulation 114 2006 688 699
40. G. Cotter, C.P. Cannon, C.H. McCabe, Y. Michowitz, E. Kaluski, A. Charlesworth Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study Am Heart J 145 2003 622 627
41. C.D. Owens, P.M. Ridker, M. Belkin, A.D. Hamdan, F. Pomposelli, F. Logerfo Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery J Vasc Surg 45 2007 2 9 discussion: 9
42. C.D. Owens, J.M. Kim, N.D. Hevelone, W.J. Gasper, M. Belkin, M.A. Creager An integrated biochemical prediction model of all-cause mortality in patients undergoing lower extremity bypass surgery for advanced peripheral artery disease J Vasc Surg 56 2012 686 695
43. I. Carriere, A.M. Dupuy, A. Lacroux, J.P. Cristol, C. Delcourt Pathologies Oculaires Liées à l'Age Study Group Biomarkers of inflammation and malnutrition associated with early death in healthy elderly people J Am Geriatr Soc 56 2008 840 846
44. M.H. Criqui, L.A. Ho, J.O. Denenberg, P.M. Ridker, C.L. Wassel, M.M. McDermott Biomarkers in peripheral arterial disease patients and near- and longer-term mortality J Vasc Surg 52 2010 85 90
45. H. Vidula, L. Tian, K. Liu, M.H. Criqui, L. Ferrucci, W.H. Pearce Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study Ann Intern Med 148 2008 85 93
46. C. Wanner, V. Krane, W. März, M. Olschewski, J.F. Mann, G. Ruf Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
47. B.C. Fellström, A.G. Jardine, R.E. Schmieder, H. Holdaas, K. Bannister, J. Beutler Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
48. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, C.H. Hennekens Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
49. T.A. Pearson, C.M. Ballantyne, E. Veltri, A. Shah, S. Bird, J. Lin Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy Am J Cardiol 103 2009 369 374
50. S.E. Nissen, J.C. Tardif, S.J. Nicholls, J.H. Revkin, C.L. Shear, W.T. Duggan Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 2007 1304 1316
51. L. Mosca, P. Collins, D.M. Herrington, M.E. Mendelsohn, R.C. Pasternak, R.M. Robertson Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association Circulation 104 2001 499 503
52. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komajda Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
53. H.H. Feringa, S.E. Karagiannis, V.H. van Waning, E. Boersma, O. Schouten, J.J. Bax The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease J Vasc Surg 45 2007 936 943
54. S.J. Nicholls, C.M. Ballantyne, P.J. Barter, M.J. Chapman, R.M. Erbel, P. Libby Effect of two intensive statin regimens on progression of coronary disease N Engl J Med 365 2011 2078 2087
55. K.J. Ho, M. Spite, C.D. Owens, H. Lancero, A.H. Kroemer, R. Pande Aspirin-triggered lipoxin and resolving E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis Am J Pathol 177 2010 2116 2123
56. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742